Comparison of the efficacy and tolerability of ivabradine and ranolazine in patients of chronic stable angina pectoris

Journal of Pharmacology and Pharmacotherapeutics

Volumn 4, Issue 1, 2013, Pages 33-38

  Chaturvedi, Aditi ^a   Singh, Yogendra ^b   Chaturvedi, Harish ^a   Thawani, Vijay ^a   Singla, Sakshi ^c   Parihar, Deepak ^a  

^a Veer Chandra Singh Garhwali Govt Medical Sciences and Research Institute   (India)

^b ESCORTS HEART INSTITUTE AND RESEARCH CENTRE   (India)

^c HIMALAYAN INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Antianginals; dizziness; equiefficacious; nausea; serum sickness like reaction

Indexed keywords

IVABRADINE; RANOLAZINE;

ADULT; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD PRESSURE; BLURRED VISION; CHRONIC DISEASE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUGHING; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HEART RATE; HUMAN; INDIA; MALE; MUSCLE CRAMP; NAUSEA; OPEN STUDY; SERUM SICKNESS; STABLE ANGINA PECTORIS; VERTIGO; VOMITING;

EID: 84875728661     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.107663     Document Type: Article

References (18)

1. Murray CJL, Lopez AD. The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Cambridge, Harvard School of Public Health on behalf of the World Health Organization and The World Bank, 1996 (Global Burden of Disease and Injury Series, Vol. I).
2. Gravel GM, Tardif JC. Ivabradine: The evidence of its therapeutic impact in angina. Core Evid 2008;3:1-12.
3. McBride BF, White CM. Ranolazine: A novel metabolic modulator for the treatment of chronic stable angina. Formulary 2003;38:461-4.
4. Riccioni G. Ivabradine: From molecular basis to clinical effectiveness. Adv Ther 2010;27:160-7.
5. Simon L, Ghaleh B, Puybasset L, Guidicelli JF, Berdeaux A. Coronary and haemodynamic effects of S16257, a new bradycardic agent, in resting and exercising conscious dogs. J Pharmacol Exp Ther 1995;275:659-66. (Pubitemid 26023611)
6. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004;43:1375-82. (Pubitemid 38496341)
7. Borer JS, Fox K, Jaillon P, Lerebours G.; Ivabradine investigators group. Antianginal and antiischemic effects of ivabradine, an I f inhibitor, in stable angina: A randomized, double-blind, multicentered, placebo-controlled trial. Circulation 2003;107:817-23. (Pubitemid 36241038)
8. Electronic Medicines Compendium (eMC). Procoralan™ (ivabradine hydrochloride) [summary of product characteristics]. Servier Laboratories Ltd. (last updated: 09/12/2010). Available from: http://www.emc.medicines.org.uk/ medicine/17188/SPC/Procoralan [Last accessed on 19/5/2010].
9. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/persistent) sodium current: A potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J 2004;6:I3-7.
10. Ver Donck L, Borgers M, Verdonck F. Inhibition of sodium and calcium overload pathology in the myocardium: A new cytoprotective principle. Cardiovasc Res 1993;27:349-57. (Pubitemid 23116131)
11. Jonsson R, Sixt E, Landahl S, Rosenhall U. Prevalance of dizziness and vertigo in an urban elderly population. J Vestib Res 2004;14:47-52. (Pubitemid 38648168)
12. Stone PH, Chaitman BR, Koren A, Crager M. Abstract 3362: Effects of Ranolazine as monotherapy and combination therapy on rate pressure product at rest and ruring exercise: Results from the MARISA and CARISA trials. Circulation 2006;114:715.
13. Ruzyllo W, Ford IF, Tendera MT. Anti-anginal efficacy and safety of ivabradine comparedwith amlodipine in patients with stable effort angina pectoris: A 3-month randomised, doubleblind, multicentre, noninferiority trial. Drugs 2007;67:393-405. (Pubitemid 46425552)
14. Cervetto L, Demontis GC, Gargini C. Cellular mechanisms underlying the pharmacological induction of phosphenes. Br J Pharmacol 2007;150:383-90. (Pubitemid 46280644)
15. Tardif JC, Ford I, Tendera M, Bourassa MG, Fox K. Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J 2005;26:2529-36. (Pubitemid 41677303)
16. Serum Sickness Like reaction from Wikipedia, the free encyclopedia (last modified on 26 April 2011). Available from: http://www.en.wikipedia.org/wiki/ Serum-sickness-like-reaction [Last accessed on 19/5/2011].
17. Drug Details PROCORALAN 5 mg and 7.5 mg coated tablets. Available from: http://www.epgonline.org/mobile/drug-details.cfm/id/DR004072/page/atoz/letter/P/ language/LG0001/startrow-drug/161/drugName/PROCORALAN-5-mg-and-7. 5-mg-coated-tablets [Last accessed on 20/5/2011].
18. Mener DJ, Negrini C, Blatt A. Itching like mad. Am J Med 2009;8:732-4.